Skip to main content

Table 3 Adverse events

From: ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

Systemic, n° of patients (%)

3 (11.5%)

Local, n° of patients (%)

6 (23.1%)

 Pain

3 (11.5%)

 Bladder spasm

3 (11.5%)

 Dysuria

5 (15.4%)

 Hematuria

1 (3.8%)

 Difficult catheter insertion

1 (3.8%)

 Frequency/urgency

3 (11.5%)

 Nocturia

2 (7.7%)